EIV Capital Taps Mo Bawa to Lead Middle Market Healthcare Push

EIV Capital, a middle-market private equity firm with $2.6 billion under management, hired Mo Bawa as a partner this week — a signal the Boston-based investor is making a harder push into healthcare buyouts at a moment when the sector's fundamentals look better than they have in years.

Bawa spent 15 years at Webster Equity Partners, most recently as a partner leading healthcare investments. He worked on more than $3 billion in transactions across physician practices, specialty services, and healthcare IT — the exact subsectors EIV has flagged as core targets as it deploys capital from its third flagship fund, closed at $1.35 billion last year.

The hire comes as private equity's relationship with healthcare is shifting. After years of regulatory scrutiny and margin compression in certain corners of the market, investors are redirecting capital toward value-based care models and specialty verticals where reimbursement tailwinds are stronger and political heat is lower. EIV's move to bring in someone who's built platforms in those exact areas suggests the firm sees a narrow but deep window to consolidate fragmented provider markets.

"Healthcare services remains one of the most compelling sectors for private equity, but the playbook has changed," Bawa said in the announcement. "The firms that win over the next five years will be the ones that understand how to build real clinical and operational value — not just financial engineering."

Bawa joined Webster Equity in 2011, back when the firm was still a sub-$500 million fund manager focused on lower middle-market services businesses. Over the next decade and a half, he led or co-led investments in anesthesiology, dermatology, ophthalmology, and women's health platforms — sectors that have since become some of the most active consolidation plays in healthcare PE.

His notable deals include the formation and exit of a multi-state dermatology platform and the build-out of a specialty surgical services business that scaled to over 200 providers across 15 states. Both exits delivered north of 3x returns, according to people familiar with the transactions, at a time when healthcare services multiples were compressing industry-wide.

What made those wins replicable wasn't just picking the right verticals. Bawa's reputation in the market is for operational intensity — embedding clinical workflows, recruiting physician leaders who can scale culture, and building payer relationships that create defensibility beyond just site count. That's table stakes now, but it wasn't in 2015 when roll-ups were still largely about multiple arbitrage.

EIV's existing healthcare portfolio tilts heavily toward those themes. The firm's current investments include a home health platform, a behavioral health network, and a value-based primary care business — all models where clinical quality directly affects unit economics. Bringing in someone who's already built and exited businesses in adjacent categories gives EIV the operational muscle to move faster on new deals without rebuilding institutional knowledge from scratch.

Private equity healthcare deal volume hit a three-year high in Q1 2026, according to PitchBook, with 187 transactions totaling $14.3 billion — up 22% year-over-year. But the composition of that activity matters more than the headline number. Mega-cap hospital system take-privates and large physician practice roll-ups are down. Middle-market deals in high-acuity specialties and value-based care are up sharply.

The shift reflects three tailwinds converging at once. First, Medicare Advantage penetration is now above 55%, creating sustainable patient flow into capitated care models that reward efficiency and outcomes over volume. Second, regulatory pressure on traditional fee-for-service practices is intensifying — from staffing ratio mandates to transparency rules — making independent operators more willing to sell. Third, debt markets have stabilized after two years of volatility, bringing financing costs back to levels that make add-on acquisitions economical again.

But the market isn't uniformly attractive. Emergency medicine, revenue cycle management, and certain dental subspecialties are seeing valuation compression as reimbursement headwinds and regulatory risk weigh on buyer appetite. The winners are businesses with direct patient relationships, recurring revenue, and clinical models that align incentives between payers and providers.

That's where EIV is concentrating its firepower — and where Bawa's track record is most relevant. His prior platforms were built in verticals where commercial and government payers were both expanding coverage and where physician employment models could scale without sacrificing clinical autonomy. Those same dynamics are now playing out in women's health, specialty surgery centers, and certain diagnostic categories.

Source: PitchBook, LCD Comps, firm interviews

The FTC and state attorneys general aren't done with healthcare PE. Over the past 18 months, regulators have blocked or challenged deals in anesthesiology (Welsh Carson's U.S. Anesthesia Partners settlement), dermatology (multiple state-level investigations), and emergency medicine (TeamHealth bankruptcy fallout). The common thread: allegations that consolidation reduced competition, raised prices, or degraded care quality.

EIV manages about $2.6 billion across three funds and has invested in more than 50 companies since its founding in 2006. The firm's strategy leans toward founder-owned businesses in fragmented verticals where operational improvements and buy-and-build strategies can drive returns without relying on multiple expansion. Healthcare represents roughly 35% of the current portfolio by capital deployed.

Bawa's addition does two things for the firm. First, it gives EIV a named healthcare investment leader — someone who can front relationships with management teams, broker intermediaries, and health system executives who control referral networks. That matters in a market where proprietary deal sourcing is the difference between paying 9x EBITDA and 12x for the same asset.

Second, it signals to LPs that the firm is serious about sector specialization at a time when generalist middle-market funds are struggling to differentiate. EIV's Fund III is still in deployment mode, and having a dedicated healthcare partner with exits on their resume makes the firm more competitive for the next fundraise. LPs increasingly want evidence that a firm has the operating chops to navigate regulatory complexity and reimbursement volatility — Bawa's track record checks both boxes.

The firm didn't disclose Bawa's equity stake or compensation structure, but industry norms for lateral partner hires at middle-market funds typically include carried interest participation in the current fund and a seat on the investment committee. Given EIV's existing healthcare exposure, it's likely Bawa will also inherit oversight of one or more existing portfolio companies — giving him immediate operational responsibility alongside deal origination.

EIV's current healthcare assets include BrightSpring Health Services (home and community-based care), Thriveworks (outpatient mental health), and Privia Health (value-based primary care enablement). All three businesses are in growth mode and actively acquiring — meaning Bawa will have live M&A processes to plug into from day one.

EIV competes for healthcare deals with a crowded field of middle-market specialists: Shore Capital, FFL Partners, Gryphon Investors, Webster (Bawa's former firm), and a handful of healthcare-dedicated funds like Varsity Healthcare Partners and SV Health Investors. The differentiation comes down to operational resources, speed of execution, and willingness to back founder-led businesses versus pure financial roll-ups.

Firms that offer embedded clinical operating partners, revenue cycle optimization teams, and payer contracting expertise are winning more competitive processes — especially in specialties where physician culture matters and aggressive financial engineering can destroy value. Bawa's background suggests EIV is leaning into that model rather than competing purely on price or leverage.

If you're a founder running a $10-50 million EBITDA healthcare services business, the Bawa hire is a data point worth noticing. It tells you that sophisticated middle-market buyers are staffing up for sustained deal activity — not pulling back. That's typically a signal that valuations have stabilized and that buyers expect exit markets to cooperate over a 4-6 year hold period.

It also tells you that the buyers who are hiring are the ones expecting to move quickly. EIV closed Fund III less than 18 months ago. Adding a senior partner mid-deployment cycle means the firm either has a pipeline of deals already in diligence or expects origination volume to accelerate sharply. Either way, it's not a passive hire.

For physician practice owners in dermatology, ophthalmology, orthopedics, or gastroenterology — the verticals where Bawa built his reputation — this is a firm to keep on your shortlist. The same goes for founders in women's health, urology, and specialty surgery centers, where platform consolidation is still in early innings and where clinical quality differentiates more than site count.

The flip side: if you're building a business in a subsector that's already seen heavy consolidation (anesthesiology, emergency medicine, hospital-based specialties), expect more scrutiny on unit economics, payer mix, and regulatory exposure. The easy money phase of those roll-ups is over. The firms still active in those markets are doing it because they have a specific operational thesis — not because they're chasing deal count.

Three questions separate serious buyers from financial tourists in today's healthcare market. One: What operational resources are you embedding post-close, and who on your team has scaled a business in my specific specialty before? Two: How are you thinking about regulatory risk, and what's your track record navigating FTC scrutiny or state-level investigations? Three: What's your payer strategy — are you building for fee-for-service optimization, value-based care transition, or both?

Firms that can't answer those questions crisply are the ones still treating healthcare like a generic services roll-up. The ones that can — and EIV's Bawa hire suggests they're in that camp — are the ones likely to still be standing when the next cycle turns.

Bawa's move is part of a wider pattern across middle-market PE: firms are hiring senior operating partners and sector specialists at a faster clip than they're adding general investment professionals. That shift reflects LP pressure for demonstrable sector expertise and operational value creation — not just financial engineering and multiple arbitrage.

Over the past 12 months, at least a dozen middle-market firms have announced senior hires with deep industry backgrounds in healthcare, industrials, or software. In many cases, those hires precede fundraising announcements by 6-12 months. It's a way to de-risk the next fund pitch: show LPs you've got the team in place to execute the strategy you're selling.

EIV hasn't announced plans for Fund IV yet, but the typical deployment cycle for a middle-market fund is 3-4 years. Fund III closed in late 2024, meaning the firm is likely starting to think about the next raise in 2026 or early 2027. Bringing in a healthcare partner with a strong track record now sets the stage for that conversation — and gives the firm time to show LPs results before making the formal ask.

It's also a retention play. Senior talent in healthcare PE is scarce, and firms that don't offer partnership tracks risk losing associates and vice presidents to competitors or to operating roles at portfolio companies. By promoting from within and bringing in proven external hires like Bawa, EIV signals to its junior team that there's a clear path to the top — which matters when you're trying to keep investment talent from jumping ship.

EIV describes itself as a "growth-oriented middle-market firm focused on founder-owned businesses in healthcare, business services, and specialty manufacturing." That's consultant-speak for: we buy profitable, growing companies where the founder still owns the majority, and we help them scale through M&A and operational improvements.

The firm's typical check size is $50-150 million in equity, targeting businesses with $10-50 million in EBITDA. That puts them squarely in the middle market — big enough to compete for quality assets, small enough to avoid the mega-cap complexity and regulatory scrutiny that comes with billion-dollar healthcare platforms.

Healthcare represents about a third of the portfolio, but it's the sector where the firm has seen the most consistent exits and return generation. That makes doubling down on healthcare a rational capital allocation decision — especially if you believe the fundamentals are improving and the competitive dynamics favor firms with operating expertise over pure financial buyers.

Bawa's hire also gives EIV more flexibility to pursue founder-led deals in healthcare without overstretching the existing team. Founder-owned businesses require more hand-holding and relationship management than traditional auctions — the seller cares about culture fit, post-close governance, and how the business will be operated under new ownership. Having a partner who can speak credibly to those concerns increases EIV's win rate in proprietary processes.

Based on Bawa's background and EIV's existing portfolio, expect the firm to target three specific healthcare verticals over the next 12-18 months. First, specialty physician practices in high-acuity areas with strong commercial payer mix — think orthopedics, urology, gastroenterology, or women's health. These are categories where consolidation is still fragmented, where reimbursement is stable or growing, and where clinical quality creates defensible competitive moats.

Second, value-based care enablement businesses — not the primary care platforms themselves, but the tech, analytics, and care coordination infrastructure that supports them. This includes risk adjustment software, population health management tools, and remote patient monitoring platforms. These businesses generate recurring revenue, have high gross margins, and benefit from the same Medicare Advantage tailwinds driving primary care consolidation.

Third, specialty surgery centers in outpatient settings. As procedures continue to migrate out of hospitals and into ambulatory surgery centers (ASCs), the best-positioned platforms are those that own both the real estate and the clinical operations, maintain strong payer relationships, and can recruit top surgeons without sacrificing quality. Bawa's experience building multi-site specialty platforms maps directly to this opportunity.

One wildcard: women's health. It's a category that's seen relatively light PE activity compared to other specialties, but the fundamentals are compelling — growing patient demand, favorable reimbursement trends, and a highly fragmented provider landscape. If EIV moves into this vertical, it'll be a signal that the firm sees a white space opportunity that other middle-market players are still sleeping on.

Mo Bawa's hire at EIV Capital is a single data point, but it's a telling one. It says that sophisticated healthcare investors are still staffing up, still deploying capital, and still betting that the next five years will create meaningful opportunities in provider consolidation. But it also says that the playbook has changed — and the firms winning deals are the ones bringing operational muscle, regulatory savvy, and sector-specific expertise to the table.

For founders, that's good news if you're building a defensible business in the right vertical. It's less good news if you're running a financial roll-up in a category that's already oversaturated or facing regulatory headwinds. The money is still flowing into healthcare PE — it's just flowing more selectively than it did three years ago.

For EIV, the Bawa hire is both a near-term deployment accelerant and a long-term positioning move. It gives the firm the credibility and capacity to compete for the best healthcare deals in the market today — and it sets the stage for a stronger fundraising pitch when Fund IV comes to market in a year or two.

And for the broader middle market? It's a reminder that talent moves signal strategy. When firms hire senior operators with deep sector expertise, it's because they see a sustained opportunity — not just a short-term window. Healthcare services consolidation isn't over. It's just entering a phase where the firms with the best teams and the sharpest theses are the ones that'll capture the returns.